Breztri Aerosphere

Phase 3Small molecule

AstraZeneca

Breztri Aerosphere is one of 45 small molecule programs targeting Moderate to Severe COPD. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Moderate to Severe COPDRecruiting

Efficacy and SafetyUnknown status

Moderate to Severe COPDPhase 3

Recruiting

Efficacy and SafetyPreclinical

Unknown status

Competition

Competitive Landscape

228 competitors in Efficacy and Safety

#DrugCompanyPhaseTrials

Rinvoq

AbbVie

Phase 3

4 2

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

7 3

Rapamune

PPrism Pharmaceuticals

Phase 3

5 4

Rilutek

AAzurity Pharmaceuticals

Phase 3

3 5

BESREMI

PPharmaEssentia

Phase 3

2 6

Kineret

SSwedish Orphan Biovitrum

Phase 3

2 7

UPLIZNA

HHorizon Therapeutics Ireland DAC

Phase 3

1 8

Becotatug Vedotin

FFudan University

Phase 3

1 9

Apatinib Mesylate

BBukwang Pharmaceutical

Phase 3

1 10

Raphamin

MMateria Medica Holding

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

ApprovedRecruiting

Moderate to Severe COPD

NCT06531798

Clinical

Trials by Indication[1]

Efficacy and Safety1 trial

Efficacy and Safety of Perioperative Use of Breztri Aerosphere to Relieve Cough After Lobectomy

Unknown status·JJianxing He·N/A·NCT05472350·128 enrolled

Moderate to Severe COPD1 trial

Post-marketing Phase IV, Multicenter, Prospective Study to Observe the Safety and Tolerability of Breztri aerosphereTM Containing a Fixed Dose Combination of Budesonide 160 mcg/ Glycopyrronium 7.2 mcg/ Formoterol Fumarate Dehydrate 5 mcg in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Recruiting· AstraZeneca logo

AstraZeneca·Approved·NCT06531798·166 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Breztri Aerosphere. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Breztri Aerosphere compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Breztri Aerosphere. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

Breztri Aerosphere

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Efficacy and Safety1 trial

Moderate to Severe COPD1 trial

References

Drug Info

Quick Facts

Related News